Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
24.24
+0.88 (3.83%)
Nov 21, 2024, 10:44 AM EST - Market open
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
49
Market Cap
158.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 138.00K | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organigram Holdings | 110.30M |
| Pro-Dex | 56.80M |
| 2seventy bio | 45.62M |
| Myomo | 25.24M |
| Jin Medical International | 20.13M |
| EUDA Health Holdings | 3.81M |
| Checkpoint Therapeutics | 47.00K |
TIL News
- 2 months ago - Crude Oil Surges Over 1%; Instil Bio Shares Plunge - Benzinga
- 2 months ago - Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - GlobeNewsWire
- 2 months ago - Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements - Seeking Alpha
- 3 months ago - Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody - GlobeNewsWire
- 6 months ago - Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - Instil Bio Announces Strategic Update - GlobeNewsWire